Mount Sinai Fertility part of Sinai Health, is an academic centre associated with renowned Lunenfeld-Tanenbaum Research Institute and University of Toronto. All MSF staff and fellows are actively involved in carefully designing and conducting multiple research projects in various areas of fertility to provide the best care for our patients.

 

Research allows our team to better comprehend the ever evolving field of fertility and provides evidence where we base our decisions in providing evidence-based care and treatment for our patients. In depth, we conduct research studies to improve patient care and education, to provide better access to fertility care, and to enhance our knowledge to better care for patients. Our ultimate goal is to better the outcome of patients through increase in implantation rate, pregnancy and live birth rate.

Current Research Studies

We are actively looking for participants for the following studies. If you are interested in participating in any studies or finding out more about these opportunities, please contact the clinical research coordinator, at [email protected] or call at 416-586-4800 ext 7151.

IVF vs. ICSI Pilot Survey Study

Objective

To determine the future feasibility of performing a multi-centred, prospective, randomized controlled trial in Canada of using ICSI versus conventional IVF for couples/patients with non-male factor infertility.

Who can participate?

Participants undergoing their first IVF treatment.

 

What is involved?

Participants will be asked to complete a short survey.

Dual Trigger Study

Objective

To evaluate whether the use of a “dual-trigger” (Superfact + Pregnyl) can improve IVF outcomes, compared to GnRH-a alone, in patients at high risk of OHSS undergoing a freeze-all cycle.

To determine if frozen embryo transfer occurring on the sixth day or the seventh day of progesterone supplementation will lead to lower miscarriage rates.

Who can participate?

Participants who are considered at risk of developing OHSS and undergoing IVF treatment.

 

What is involved?

Participants will be randomized into two groups: treatment arm (Suprefact® + Pregnyl®) vs. control arm (Suprefact® + sham-placebo).

BRCA Follicular Fluid Study

Objective

To better understand conditions that contribute to the initiation of high-grade serous ovarian cancer to develop drugs or approaches to prevent the disease.

Who can participate?

Individuals who have or will be tested for germline mutations in BRCA1 or BRCA2.

 

What is involved?

Participants will be asked to provide consent to have their follicular fluid (that is normally discarded) collected to be used for research.

Recent Publications

MSF publishes our research findings in leading scientific journals every year. Click on the links below to access full abstract.

Study Abstracts

JAMA Netw Open. 2019 Nov 1;2(11):e1914511. Covelli A, Facey M, Kennedy E, Brezden-Masley C, Gupta AA, Greenblatt E, Baxter NN.

BMC Med Inform Decis Mak. 2019 Oct 28;19(1):203. Speller B, Metcalfe K, Kennedy ED, Facey M, Greenblatt E, Scheer AS, Warner E, Joy AA, Wright FC, Baxter NN.

Arch Gynecol Obstet. 2019 Apr;299(4):1159-1164. Hilton J, Liu KE, Laskin CA, Havelock J.

J Obstet Gynaecol Can. 2019 Mar;41(3):283-291. Gill P, Axelrod C, Chan C, Shapiro H.

J Cancer Educ. 2019 Feb 28. Zwingerman R, Melenchuk K, McMahon E, Liu KE, Siren A, Laferriere N, Greenblatt EM.

Hum Mol Genet. 2019 Feb 1;28(3):372-385. Choufani S, Turinsky AL, Melamed N, Greenblatt E, et al.

J Obstet Gynaecol Can. 2018 Apr;40(4):399. No abstract available. Cohen A, Greenblatt EM.

J Obstet Gynaecol Can. 2018 Mar;40(3):293-298. Gunn B, Murphy KE, Greenblatt EM.

Mol Clin Oncol. 2018 Jan;8(1):153-158. Srikanthan A, Amir E, Bedard P, Giuliani M, et al.